/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Kiora Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.06 0.1111(11.11%) KPRX at 04 Dec 2025 04:36 PM Biotechnology
Lowest Today 1.93
Highest Today 2.06
Today’s Open 1.93
Prev. Close 1.89
52 Week High 4.18
52 Week Low 1.77
Day’s Range: Low 1.93 High 2.06
52-Week Range: Low 1.77 High 4.18
1 day return -
1 Week return +10.93
1 month return -13.06
3 month return -21.97
6 month return -33.85
1 year return -39.31
3 year return -93.65
5 year return -99.84
10 year return -

Institutional Holdings

AIGH Capital Management, LLC 6.30

Nantahala Capital Management, LLC 6.15

Stonepine Capital Management Llc 5.18

ADAR1 Capital Management LLC 4.87

Velan Capital Investment Management LP 3.56

Geode Capital Management, LLC 0.54

UBS Group AG 0.51

Fidelity Extended Market Index 0.40

Fidelity Series Total Market Index 0.10

Northern Trust Extended Eq Market Idx 0.08

NT Ext Equity Mkt Idx Fd - L 0.08

Bridgeway Omni Small-Cap Value 0.06

Bridgeway Omni Small-Cap Value N 0.06

Vanguard Institutional Extnd Mkt Idx Tr 0.05

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

Fidelity Total Market Index 0.02

Spartan Total Market Index Pool G 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

Tower Research Capital LLC 0.01

SBI Securities Co Ltd 0.01

Spartan Extended Market Index Pool F 0.00

BlackRock Inc 0.00

Citigroup Inc 0.00

Bank of America Corp 0.00

Goss Wealth Management LLC 0.00

NT Ext Equity Mkt Idx Fd - NL 0.00

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Activest Wealth Management 0.00

Advisor Group Holdings, Inc. 0.00

SSgA U.S. Total Market Index Strategy 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Citadel Advisors Llc 0.00

Morgan Stanley - Brokerage Accounts 0.00

Rosalind Advisors, Inc. 0.00

Sabby Management LLC 0.00

U.S. Bancorp 0.00

Market Status

Strong Buy: 0

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 6.92 M

PB Ratio 0.3167

PE Ratio 0.0

Enterprise Value -11.87 M

Total Assets 36.48 M

Volume 67367

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:12059 0.0M, FY19:2686000 2.7M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:12059 0.0M, FY19:2686000 2.7M

Annual Net worth FY23:-12743736 -12.7M, FY22:-13583610 -13.6M, FY21:-16394919 -16.4M, FY20:-8091940 -8.1M, FY19:-7096696 -7.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:20000 0.0M

Quarterly Profit Q3/2025:-38235 -0.0M, Q2/2025:-31496 -0.0M, Q1/2025:-19608 -0.0M, Q3/2024:null 0.0M, Q2/2024:2123 0.0M

Quarterly Net worth Q3/2025:26806 0.0M, Q2/2025:-2152459 -2.2M, Q1/2025:-2192980 -2.2M, Q3/2024:-3413326 -3.4M, Q2/2024:-2221646 -2.2M

Fund house & investment objective

Company Information Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis. It has strategic development and commercialization agreement with Théa Open Innovation for the development of KIO-301; and collaboration and development agreement with Global Genes for treating rare ocular disorders. The company operates in the United States, Austria, and Australia. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Organisation Biotechnology

Employees 12

Industry Biotechnology

CEO Dr. Brian M. Strem Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow